⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 26, 2024Open Access

TABLE 1 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Patient demographics and characteristics

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bitting et al. (2024) studied this question.

synapsesocial.com/papers/68e779deb6db6435876ee179 https://doi.org/10.1158/2767-9764.25288979

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1TABLE 1 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma2024
2TABLE 3 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma2024
3TABLE 3 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma2024
4TABLE 2 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma2024
5TABLE 2 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma2024